MIST MIST
Company Profile ↓Company Overview
MIST (MIST) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -23.15% |
| 6 Months: | -41.88% |
| 3 Months: | -39.10% |
| 1 Month: | -11.24% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.88 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 61.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | 238.00K |
| Operating Income | -4.25M | -3.68M | -5.79M | -10.93M | -14.33M | -13.72M | -16.76M | -13.11M | -12.09M | -12.59M | 712.00K | -14.27M | -14.05M | -16.81M | -15.03M | -15.50M | -16.44M | -15.36M | -10.48M | -9.66M | -9.62M | -20.52M | -12.53M | -11.83M | -23.66M |
| Net Income | -4.18M | -3.59M | -5.70M | -10.45M | -13.66M | -12.83M | -16.34M | -12.98M | -11.98M | -12.51M | 770.00K | -14.22M | -14.01M | -16.65M | -14.56M | -14.95M | -16.04M | -15.08M | -10.35M | -9.36M | -9.44M | -20.76M | -12.97M | -11.92M | -26.07M |
| Diluted EPS | - | - | - | - | - | - | - | -0.53 | - | -0.30 | 0.02 | -0.34 | -0.33 | -0.39 | -0.34 | -0.35 | -0.37 | -0.35 | -0.21 | -0.14 | -0.14 | -0.31 | -0.20 | -0.12 | -0.20 |
| R&D Expense | 3.09M | 2.55M | 3.91M | 7.76M | 10.53M | 9.54M | 11.87M | 8.62M | 8.23M | 8.60M | 9.43M | 9.73M | 8.77M | 10.66M | 9.83M | 10.26M | 8.62M | 6.72M | 3.64M | 2.81M | 3.96M | 4.98M | 3.67M | 3.94M | 3.25M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Income | -23.82M | -57.88M | -50.71M | -43.07M | -59.64M | -61.10M | -42.10M | -62.14M |
| Net Income | -23.18M | -55.23M | -49.97M | -42.85M | -58.39M | -59.69M | -41.52M | -63.06M |
| Diluted EPS | - | - | -1.70 | -1.02 | -1.38 | -1.39 | -0.67 | -0.75 |
| R&D Expense | 16.85M | 41.98M | 34.49M | 38.67M | 39.83M | 31.05M | 14.36M | 18.11M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 88.08M | 123.43M | 149.97M | 119.85M | 74.48M | 75.23M | 75.50M | 113.56M |
| Total Equity | 25.98M | 83.55M | 114.92M | 143.12M | 112.60M | 66.35M | 16.77M | 13.15M | 41.77M |
| Cash & Equivalents | - | 85.95M | 119.82M | 72.31M | 114.14M | 7.64M | 13.76M | 25.31M | 73.05M |
| Long Term Debt | - | - | 0 | - | - | - | 49.77M | 53.35M | 57.19M |
| Total Liabilities | - | 4.53M | 8.51M | 6.86M | 7.25M | 8.13M | 58.45M | 62.35M | 71.79M |
| Current Liabilities | - | 4.53M | 8.33M | 6.16M | 6.78M | 6.14M | 7.23M | 8.13M | 13.98M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -21.05M | -51.15M | -50.73M | -33.22M | -52.47M | -46.42M | -28.85M | -49.04M |
| Investing Cash Flow | 16.00M | -384.00K | -70.00M | 70.00M | -57.12M | 4.76M | 8.28M | 11.25M |
| Financing Cash Flow | 80.11M | 85.41M | 73.22M | 5.05M | 3.09M | 47.79M | 32.12M | 85.53M |
| Capital Expenditure | -5.00K | -413.00K | - | - | -272.00K | -112.00K | -33.00K | -302.00K |
| Free Cash Flow | -21.05M | -51.56M | - | - | -52.74M | -46.54M | -28.88M | -49.34M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - |
| ROE % | -27.8% | -48.1% | -34.9% | -38.1% | -88.0% | -355.9% | -315.8% | -151.0% |
| ROCE % | -28.5% | -50.3% | -35.3% | -38.1% | -87.3% | -89.8% | -62.5% | -62.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MIST
Milestone Pharmaceuticals sets Aug. 12, 8:30 a.m. webcast - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNZmRfd1B6Yzd5amxVUDFfTmRrOGUwVkltejJQV0xJTHNiZ2xhYmpmXzR1VDNPRE9CMnJWMzRXeUN1eUdSTm5iY0RzVXdoMnVyWWJFcnUza0VySWs5dTRkc3E1bEdrQmdMMS1xd21PQjFtUUU0SE9fbzVZRWlRMTcwUHVUZlg2by0ybG45Mk…
Milestone Pharmaceuticals: Here Comes The Revenue Ramp (NASDAQ:MIST) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxOSERXTXBoSWNMclN4dWN6MzduMlkwRDRfT1Vmbm53bkFuMWFUX1lwODM4MFQ3a0NTNHdNSUFxMUkzNkNaTXF5QmI2XzFfdFk2MHh6UjRrbDdXN0ZxY3R0QldWWnZibHdxZ2d4emFEeGNvMkV3V00yaE1SVUNQdklQdnVXTWRYMGZvVzI4SH…
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Milestone Pharmaceuticals (MIST) - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxOM1hheHpCZVBSTDhYVGZqWElTanhQeVcyNVZ5VlNiZ3M0eWk3T0hPTzRHa3M5MXV5MEs4OVpBb1J3T1dhS0xmMERwV2JaekJia0lkLTVqWWR5TERweTBGYk1aLTJmbGZIUGpFVXB1ZDJSSGttUlF4d2NVU2dLOVhEcW9qRzVsT3ZDTlJYOX…
$MIST stock is up 10% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQMVVMaXE0M3M5QTV3VTlnYlBHcFJfZy1SUE5nY3ItZlAxMnNGSDFXcVVFR0FyRm9Bc2ZhRkw0OVp6MVE3SWV4OE9WbmtPamdHZFNzcTdRTzB4dm9oZ3U4cTdneHFpWmJjdS1TeU5Yc2xaYmUxRWw2czJZQzNLRFhtbWI3UHRXbTVmZnhxZk…
Enterprise value to EBITDA forward of Milestone Pharmaceuticals Inc. – NASDAQ:MIST - TradingView
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQSHpKel82cFFmYWU5c3hCZlNoM3dwNEV5UU9yRG5IbktKTjU3VjhWQVVYQlZtMHNpbENDVzZLbmgxTWtDQVJSU1lwSEFvNDQ2UUdHZjAzX21FXzFPa3VncHVaRUltVTVqUTBSaHpYUmYyNENfUjhPZDR5S1M4QnRoQ0QxcUdvUzN3dWhNa3…
Milestone Pharmaceuticals Inc (MIST) Institutional Confidence - TradingKey
<a href="https://news.google.com/rss/articles/CBMiZ0FVX3lxTFB4TUlDdVJnNWg1Y0JuOHBwVk9mT2FkMnpXYk45T2Rhd29lYWRPZ1gzbGctX2hQVlBFcGwyMl9zdkZMMzVnYnRaalZzTkRkTFJoRnJGLXp4QlBGREhvOXQ4U2lFMFRPTVk?oc=5" target="_blank">Milestone Pharmaceuticals In…
MIST — Frequently Asked Questions
What is the current share price of MIST?
As of 2026-08-05 17:25 PDT, MIST trades at $1.14 on NASDAQ/NYSE. Its 52-week range is $1.01 to $2.95.
What is the P/E ratio of MIST?
MIST trades at a trailing price-to-earnings (P/E) ratio of -1.52.
Is MIST a good stock to buy?
This page provides a data-driven analysis of MIST, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.